Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Sponsor: Boryung Pharmaceutical Co., Ltd
Summary
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Official title: A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
204
Start Date
2025-06-11
Completion Date
2026-10-01
Last Updated
2025-09-15
Healthy Volunteers
No
Conditions
Interventions
Metformin
The dosage and dose frequency are maintained as they were before the screening.
Dapagliflozin/Pioglitazone
Dapagliflozin 10mg/Pioglitazone 30mg QD
Dapagliflozin/Sitagliptin
Dapagliflozin 10mg/Sitagliptin 100mg QD
Locations (1)
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seocho District, South Korea